What Labman’s involvement in the UK bio-manufacturing strategy means for industry

Labman joins multi-million-pound national incentive to speed up UK bio-manufacturing innovation

Labman recently announced its part in the UK Government’s newly announced multi-million-pound investment to speed up advanced science, engineering, biology, and cutting-edge drug manufacturing.

With Innovate UK’s Sustainable Medicines Manufacturing Innovation Programme (SMMIP), Labman will aid in the production of sophisticated automation and smart bioprocessing infrastructure necessary to speed up the “Sustainable Future Factory” vision.

Labman is contributing to this goal through its fast-developing Bioprocessing business unit, providing significant expertise in GMP-compliant automation, smart QC workflows, and scalable robotic systems that bridge the gap between early-stage R&D and industrial manufacturing.

Image Credit: Labman

Labman’s modular, automated platforms support the initiative’s goals to:

• Increase the UK’s biomanufacturing capacity via flexible facilities that are automation-ready
• Speed up the transition from scientific discovery to products that work in the real world
• Boost quality and reproducibility via smart QC automation
• Facilitate compliance-ready scale-up, assisting innovators' progress with speed and safety to regulated production

This investment couldn’t come at a more exciting time. The UK has world-class scientific talent, and now we’re matching it with world-class automation. At Labman, we’re building the GMP-ready, quality-driven bioprocessing systems that will let researchers and manufacturers scale with confidence. Our aim is simple: give innovators the automation tools they need to bring breakthrough therapies and biologics into the world faster, safer, and more sustainably.

Tom Smith, BioProcessing Automation Lead, Labman 

Labman’s well-established expertise in GMP automation, electronic batch record integration, in-line QC, and robotic bioprocessing workflows positions the organization uniquely to support this national program.

Building on the growing momentum of its new AI-driven bioreactor project, Labman is showing how smart automation can enhance the early stages of bioprocess development. The company facilitates regular, audit-ready manufacturing from day one, helping to mitigate the risks associated with scale-up. This approach supports the UK’s new wave of biotech innovators in moving quickly into regulated environments.

This project marks a critical step towards building a robust, globally competitive engineering biology and medicines manufacturing ecosystem. Labman is happy to be spearheading that future.

Sub-sampler being developed as part of the AI-optimized BALANCE platform. Image Credit: Labman

About Labman

Labman is a global leader in creating custom automated laboratory technologies, products, and software that empower and advance scientific discovery.

We collaborate across diverse industries, including medical, pharmaceutical, agritech, paints and coatings, and FMCG, to deliver innovative solutions.

From our state-of-the-art manufacturing facilities, Labman’s multi-disciplinary teams design, build, and support systems used worldwide, enabling groundbreaking science in leading laboratories every day.

Sponsored Content Policy: News-Medical.Net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.